FI963281L - Ureaasipohjainen rokote ja helicobakteeri-infektion hoito - Google Patents

Ureaasipohjainen rokote ja helicobakteeri-infektion hoito Download PDF

Info

Publication number
FI963281L
FI963281L FI963281A FI963281A FI963281L FI 963281 L FI963281 L FI 963281L FI 963281 A FI963281 A FI 963281A FI 963281 A FI963281 A FI 963281A FI 963281 L FI963281 L FI 963281L
Authority
FI
Finland
Prior art keywords
urease
treatment
helicobacter pylori
based vaccine
pylori infection
Prior art date
Application number
FI963281A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI963281A0 (fi
FI963281A7 (fi
Inventor
Pierre Michetti
Irene Corthesy-Theulaz
Andre Blum
Catherine Davin
Rainer Haas
Jean-Pierre Kraehen-Buhl
Emilia Saraga
Original Assignee
Oravax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oravax Inc filed Critical Oravax Inc
Publication of FI963281A0 publication Critical patent/FI963281A0/fi
Publication of FI963281A7 publication Critical patent/FI963281A7/fi
Publication of FI963281L publication Critical patent/FI963281L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI963281A 1994-02-23 1995-02-23 Ureaasipohjainen rokote ja helicobakteeri-infektion hoito FI963281L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/200,346 US6290962B1 (en) 1992-11-03 1994-02-23 Urease-based vaccine and treatment for helicobacter infection
PCT/US1995/002202 WO1995022987A1 (fr) 1994-02-23 1995-02-23 Vaccin et traitement fondes sur l'urease en vue de soigner l'infection due a helicobacter

Publications (3)

Publication Number Publication Date
FI963281A0 FI963281A0 (fi) 1996-08-22
FI963281A7 FI963281A7 (fi) 1996-10-22
FI963281L true FI963281L (fi) 1996-10-22

Family

ID=22741337

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963281A FI963281L (fi) 1994-02-23 1995-02-23 Ureaasipohjainen rokote ja helicobakteeri-infektion hoito

Country Status (15)

Country Link
US (2) US6290962B1 (fr)
EP (1) EP0751786A4 (fr)
JP (1) JPH09509661A (fr)
AU (1) AU694195C (fr)
BR (1) BR9506884A (fr)
CA (1) CA2184057A1 (fr)
CZ (1) CZ250396A3 (fr)
FI (1) FI963281L (fr)
HU (1) HUT75374A (fr)
NO (1) NO963508L (fr)
NZ (1) NZ282535A (fr)
OA (1) OA10372A (fr)
PL (1) PL179149B1 (fr)
SK (1) SK109496A3 (fr)
WO (1) WO1995022987A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
US5871749A (en) * 1993-07-27 1999-02-16 Csl Limited Therapeutic treatment of H. pylori associated gastroduodenal disease
AU723063B2 (en) * 1995-04-28 2000-08-17 Oravax, Inc Multimeric, recombinant urease vaccine
CN1201395A (zh) * 1995-10-09 1998-12-09 科泰克斯国际有限公司 治疗幽门螺杆菌感染的方法
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
SE9600647D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Ny användning
PT885013E (pt) * 1996-04-15 2002-01-30 Anton Mayr Prof Dr Med Vet Dr Utilizacao de indutores de para-imunidade multipotentes baseados em poxvirus ou parapoxvirus atenuados e nao imunogenicos para a fabricacao de medicamentos
EP0935965A4 (fr) * 1996-04-23 2002-01-23 Toray Industries Agent anti-pylori
NZ333250A (en) * 1996-06-10 2000-05-26 Thomas Boren Helicobacter pylori blood group antigen binding adhesion protein
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
US20020026035A1 (en) * 1997-04-01 2002-02-28 Harold Kleanthous Helicobacter ghpo 1360 and ghpo 750 polypeptides and corresponding polynucleotide molecules
JP3430853B2 (ja) 1997-04-11 2003-07-28 株式会社ゲン・コーポレーション 胃炎、胃潰瘍および十二指腸潰瘍の予防剤並びに治療剤
FR2762788B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter pour usage par voie systemique sous-diaphragmatique
FR2762787B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
CA2287976A1 (fr) * 1997-04-30 1998-11-05 Bruno Guy Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US6599509B2 (en) 1997-09-02 2003-07-29 Massachusetts Institute Of Technology Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease
US5985631A (en) * 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
US20020151462A1 (en) * 1998-02-19 2002-10-17 Ling Lissolo Helicobacter pylori membrane proteins
GB9807721D0 (en) * 1998-04-08 1998-06-10 Chiron Spa Antigen
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
US6576244B1 (en) 1998-06-19 2003-06-10 Acambis, Inc. LT and CT in parenteral immunization methods against helicobacter infection
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US7041296B1 (en) * 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2351110A1 (fr) * 2000-07-17 2002-01-17 Akzo Nobel N.V. Vaccin contre les infections a helicobacter felis
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
AU2002346249B2 (en) 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
AU2002346424A1 (en) * 2001-11-19 2003-06-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
US20030118658A1 (en) * 2001-12-21 2003-06-26 Trogolo Jeffrey A. High aspect ratio encapsulated inorganic antimicrobial additive for controlled release
US7357949B2 (en) * 2001-12-21 2008-04-15 Agion Technologies Inc. Encapsulated inorganic antimicrobial additive for controlled release
FR2837835B1 (fr) * 2002-03-29 2007-06-22 Maria Urdaci Souche bacillus subtilis cu1, son utilisation comme agent immunomodulateur du systeme immunitaire et vaccin recombinant vivant contre h. pylori la contenant
CN1212126C (zh) * 2002-07-09 2005-07-27 中国科学院长春应用化学研究所 纳米羟基磷灰石补钙剂
JP2004041084A (ja) * 2002-07-11 2004-02-12 Japan Science & Technology Corp ヘリコバクター・ピロリ菌に対するワクチン用ペプチド、それをコードする遺伝子、その遺伝子が導入された形質転換体、及びそれらの利用方法
US7264800B2 (en) 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
UA81634C2 (ru) * 2002-07-18 2008-01-25 Хеликс Биофарма Корп. Фармацевтическая композиция уреазы для ингибирования роста раковых клеток и ее применение
US20040109905A1 (en) * 2002-09-18 2004-06-10 Debasis Bagchi Method and composition of anthocyanin-rich berry extracts that prevents or inhibits angiogenesis and helicobacter pylori and acts as a powerful antioxidant that provides various health benefits
WO2006016238A2 (fr) * 2004-08-04 2006-02-16 Applied Research Systems Ars Holding N.V. Capsules contenant des cellules transitoirement transfectées, procédé servant à préparer celles-ci et utilisations de celles-ci
EP1789094B1 (fr) 2004-08-13 2014-12-10 MARSHALL, Barry J. Vecteur d'administration bactérien
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
AU2007317206B2 (en) * 2006-11-10 2013-04-18 Ondek Pty Ltd Methods and devices for the delivery of peptides into the gastric mucosa
PL218700B1 (pl) 2012-03-29 2015-01-30 Gdański Univ Medyczny Doustna szczepionka zawierająca przetrwalniki Bacillus subtilis oraz jej zastosowanie do immunizacji przeciwko Helicobacter pylori
CN103461685B (zh) * 2012-06-07 2014-10-22 中国农业科学院北京畜牧兽医研究所 瘤胃脲酶抗原组合物及其制备方法和应用及瘤胃脲酶抗原蛋白的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268278A (en) * 1984-03-30 1993-12-07 Istituto Farmacologico Serono S.P.A. Genetic expression of somatostatin as hybrid polypeptide
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5268276A (en) * 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
US5443832A (en) 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
CA2117490C (fr) 1992-02-26 2009-01-06 Timothy L. Cover Toxine vacuolisante purifiee de helicobacter pylori et methodes d'utilisation
US5859219A (en) 1992-02-26 1999-01-12 Vanderbilt University Purified vacuolating toxin from Helicobacter pylori and methods to use same
DE69333110T2 (de) * 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
ATE161181T1 (de) * 1992-07-06 1998-01-15 Nestle Sa Lactobacillus acidophilus enthaltende antigastritis-mittel
US5733740A (en) 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US5403924A (en) 1992-10-13 1995-04-04 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
US5871749A (en) 1993-07-27 1999-02-16 Csl Limited Therapeutic treatment of H. pylori associated gastroduodenal disease
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
DE19521312A1 (de) * 1995-06-12 1996-12-19 Max Planck Gesellschaft Verfahren zur Identifizierung sekretorischer Gene aus Helicobacter pylori
DE19521314A1 (de) * 1995-06-12 1996-12-19 Max Planck Gesellschaft Adhärenzgen aus Helicobacter pylori und davon codiertes Polypeptid
DE19535321A1 (de) * 1995-09-22 1997-03-27 Max Planck Gesellschaft Neues Adhäsin aus Helicobacter pylori
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
FR2745186B1 (fr) * 1996-02-26 1998-12-31 Torossian Fernand Narbey Complexe immunomodulateur et ses utilisations pour le traitement et la prevention des recidives des affections par helicobacter
AU2304097A (en) * 1996-04-05 1997-10-29 Kieta Holding S.A. Compositions and methods relating to drug discovery and detection and treatment of gastrointestinal diseases
US20030023066A1 (en) * 1996-11-14 2003-01-30 Rainer Haas Helicobacter polypeptides and corresponding polynucleotide molecules
US20030069404A1 (en) * 1996-11-14 2003-04-10 Rainer Haas Helicobacter antigens and corresponding DNA fragments
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
US5985631A (en) * 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
US20030180330A1 (en) * 2000-04-27 2003-09-25 Meyer Thomas F Method for identifying helicobacter antigens

Also Published As

Publication number Publication date
PL316007A1 (en) 1996-12-23
SK109496A3 (en) 1997-07-09
EP0751786A4 (fr) 1999-12-29
EP0751786A1 (fr) 1997-01-08
HU9602310D0 (en) 1996-10-28
US20030007980A1 (en) 2003-01-09
HUT75374A (en) 1997-05-28
FI963281A0 (fi) 1996-08-22
FI963281A7 (fi) 1996-10-22
NO963508L (no) 1996-10-21
US6290962B1 (en) 2001-09-18
NO963508D0 (no) 1996-08-22
AU694195B2 (en) 1998-07-16
AU694195C (en) 2001-07-19
OA10372A (en) 2001-11-14
AU1968195A (en) 1995-09-11
CZ250396A3 (en) 1996-12-11
NZ282535A (en) 2001-03-30
JPH09509661A (ja) 1997-09-30
PL179149B1 (pl) 2000-07-31
WO1995022987A1 (fr) 1995-08-31
BR9506884A (pt) 1997-08-19
CA2184057A1 (fr) 1995-08-31

Similar Documents

Publication Publication Date Title
FI963281A7 (fi) Ureaasipohjainen rokote ja helicobakteeri-infektion hoito
FI943171L (fi) Ureaasipohjainen rokote Helicobacter-infektiota vastaan
HUT67058A (en) Oral treatment of helicobacter infection
EE9700306A (xx) Helicobacter pylori antigeenid ja vaktsiinisegud
DK0588878T3 (da) Universal, vandbaseret medicinsk cement og dentalcement
NO891896L (no) Fremgangsmaate og innretning for behandling av medisinsk spesialavfall.
FI930577A7 (fi) HIV-infektion rokote ja hoitomenetelmä
EE9800161A (et) Vähivaktsiin ja selle valmistamismeetod
DK272688A (da) Vaccine og fremgangsmaade til fresmtilling deraf
FI951060L (fi) Formulaatioita ja hoitomenetelmiä
EP0687728A3 (fr) Reovirus souche 2177 et vaccin le contenant
FI971402A7 (fi) Menetelmä voimistettujen antigeenisten Helico-bacter-lajien ja niitä s isältävien rokotteiden valmistamiseksi
NO963892D0 (no) Anvendelse av dimeticon for lokal antibakteriell terapi og/eller hindring og terapi i forbindelse med Helicobacter pylori (HP) assosierte syndromer og infeksjonssykdommer
FI963263A0 (fi) Bromelaiinin lääkinnällinen käyttö
BR9407197A (pt) Composição farmacêutica pra tratamento imunomodulador e adjuvante
NO953003D0 (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
NO953002L (no) Anvendelse av eliprodil og enantiomerer derav for fremstilling av medisinske preparater
AU3762397A (en) Treatment and prevention of helicobacter infection
NO981594D0 (no) Behandling av infeksjoner forÕrsaket av Helicobacter pylori
FI963682L (fi) Dimetikonin käyttö paikalliseen antibakteeriseen terapiaan ja/tai Helicobacter pyloriin (HP) liittyvien syndroomien ja infektiosairauksien ehkäisyyn ja terapiaan
HU9400634D0 (en) Vaccine and diagnosticum against parvovirosis of gooses and barbari duks
FI955692L (fi) Anti-kolesteroleminen muna, rokote ja valmistusmenetelmä sekä käyttö
DK117091D0 (da) Utraditionel tandpleje og paradentosebehandling
NO923827D0 (no) Preparater og fremgangsmaate for behandling av pneumonia idyr
SE9403291D0 (sv) Inhibition of asparaginase as a method for eradication of infection with helicobacter pylori